A Phase I Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of ICP-033 in Patients With Solid Tumors
Latest Information Update: 03 Dec 2022
At a glance
- Drugs ICP-033 (Primary)
- Indications Colorectal cancer; Liver cancer; Ovarian cancer; Prostate cancer; Renal cell carcinoma; Solid tumours
- Focus Adverse reactions
- Sponsors InnoCare Pharma
- 21 Aug 2022 According to InnoCare media release, the first patient has been dosed in this study in china.
- 08 May 2022 Status changed from planning to recruiting.
- 01 Jul 2021 New trial record